Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3, Prospective, Randomized, Multi-center Clinical Study Comparing the Safety and Efficacy of BAX 855 Following PK-guided Prophylaxis Targeting Two Different FVIII Trough Levels in Subjects With Severe Hemophilia A

NCT02585960 is registered in ClinicalTrials.gov with Baxalta now part of Shire as lead sponsor.

NCT NCT02585960
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02585960 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3, Prospective, Randomized, Multi-center Clinical Study Comparing the Safety and Efficacy of BAX 855 Following PK-guided Prophylaxis Targeting Two Different FVIII Trough Levels in Subjects With Severe Hemophilia A
Lead sponsor
Baxalta now part of Shire
Phase
Phase 3
Overall status
Completed
Start date
November 23, 2015
Completion date
August 5, 2018
Enrollment
135 (actual)
Sites
83

Conditions

As the registry lists them; a condition with its own page is linked.

hemophilia a